Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries, recently shared positive results from the Phase 3 SOLARIS trial of TEV-‘749 (olanzapine) for treating schizophrenia. This investigational once-monthly subcutaneous long-acting injectable showed significant improvements in social functioning and quality of life in adult patients with schizophrenia after eight weeks of treatment. The safety profile of TEV-‘749 was found to be in line with existing olanzapine formulations, with no new safety concerns reported.
In addition to the promising results of TEV-‘749, Teva also presented data on Uzedy (risperidone), an extended-release injectable approved by the FDA for treating schizophrenia in adults. Real-world data on Uzedy showed high adherence rates and utilization among adults with schizophrenia who have unmet social needs.
Furthermore, Teva announced interim results from the Phase 4 IMPACT-TD Registry, which looked at the use of once-daily Austedo XR (deutetrabenazine) extended-release tablets and twice-daily Austedo tablets in patients with tardive dyskinesia (TD). The findings revealed differences in treatment patterns for TD patients with psychotic disorders compared to those with mood disorders.
These developments from Teva Pharmaceuticals showcase the ongoing efforts to improve treatment options and outcomes for patients with schizophrenia and related disorders. The positive results from the Phase 3 SOLARIS trial highlight the potential benefits of TEV-‘749 in enhancing social functioning and quality of life for individuals living with schizophrenia. The additional data on Uzedy and the IMPACT-TD Registry provide valuable insights into the real-world use and impact of these treatment options.
Moving forward, continued research and innovation in the field of mental health medications are essential to address the complex needs of patients with schizophrenia and related conditions. By exploring new formulations and treatment approaches, pharmaceutical companies like Teva Pharmaceuticals play a crucial role in advancing patient care and improving quality of life for individuals facing these challenges.